CTLA4 and peritoneal mesothelioma: The current immune-based therapies for peritoneal mesothelioma include the treatment with the anti-CTLA4 antibody tremelimumab, and a phase III, randomised trial is ongoing (Clinical Trial NCT01843374) [40].